주요우울증이 근로자의 생산성에 미치는 영향 : WHO-HPQ(Health and Work Performance Questionnaire)를 이용한 예비연구

김원,황태연,함병주,이준석,최병휘,김세주,서용진,강은호,우종민 大韓神經精神醫學會 2007 신경정신의학 Vol.46 No.6

Objectives : Major depressive disorder (MDD) causes patients' distress and makes socioeconomic burden, both directly and indirectly. We used the concept of lost productive time (LPT) to estimate the indirect costs and calculated both absenteeism and presenteeism among workers with MDD. Mcthods : Depression group was recruited from workers visiting psychiatric outpatient clinic who had MDD without major physical or mental disorders (N= 106). Age and sex matched healthy control group was also recruited through advertisement (M=100). All participants completed a interview using WHO Health and Work Performance Questionnaire (HPQ), Job Stress Measurement Scale for Korean Employees, and Hamilton Rating Scale for Depression. Statistical analysis was performed with independent t-test or χ² test as characteristics of values (p=0.05). Results : The number of absence (0.94-day/month vs. 0.10-day/month, P=0.015) andthe numberofearly leaving (2.56-day/month vs. 0.24-day/month, P<0.001) were significantly higher in the depression group. Depression group evaluated their Perfor-mance level much lower than controls with significant value (5.16 vs. 7.62, P<0.001). In addition, depression group estimated their performance level during the last 4 weeks lower compared to the level of past 1-year (5.16 vs 6.63, P<0.001). The estimated costs of absenteeism in depression group were higher than controls by 2,520,000 Korean Won per year, and those of presenteeism were also higher by 4,880,000 Korean Won per year. The total costs of LPT in depression group were higher than controls by 7,400,000 Korean Won, which corresponds to 26% ofmean annual salary. In addition, the level of occupational stress, such as high demand and interpersonal conflict, was higher in the depression group. Conclusion : Major depressive disorder costs substantial productivity loss to workers and their company. Presenteeism imposes more time cost than absenteeism. Effectiveness trials are needed to devise cost-effective programs for the early detection and treatment of depression at the workplace.

요추부 유합수술 후 가동인접분절의 후기변화

김홍태,강도원,유찬훈,정재호,장세앙 대한척추외과학회 1996 대한척추외과학회지 Vol.3 No.1

The spinal fusion in a lumbar region may influence biomechanically in the remained mobile segment to take over the lost motions Therefore the stress concentration on the adjacent segments may accelerate the degenerative changes, and then various late changes could occur. The aim of this study was to evaluate the late changes occuring in the adjacent segments to lumbar fusions. A retrospective review of radiographs and medical records was undertaken for 67 consecutive patients who had undergone various fusions in the lumbar region for various pathologic conditions. Included in this study were the patients who had performed active daily livings without any significant pain or disability after fusion and followed for a minimum of five years(up to 18 years with a mean of 8.3 years). The results of this study were as follows : The instability, disc narrowing, spinal stenosis, vertebral slipping, or isthmic defect were found in the adjacent segments to fusions in the patients who were followed longer, in L4-5 segment and above segment of fusion, and in the adjacent segments where a degenerative changes existed before surgery and where the angular motion increased considerably in a few years after fusion. The symptoms of these patients were responded well with conservative theraphy and no patient needed any surgical theraphy during these follow-up periods.

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial

Kim, Youjin,Kim, Kyoung-Mee,Choi, Min Gew,Lee, Jun Ho,Sohn, Tae Sung,Bae, Jae Moon,Kim, Sung,Lee, Su Jin,Kim, Seung Tae,Lee, Jeeyun,Park, Joon Oh,Park, Young Suk,Lim, Ho Yeong,Kang, Won Ki,Park, Se Ho The Korean Gastric Cancer Association 2018 Journal of gastric cancer Vol.18 No.4

Purpose: We aimed to discuss the roles of radiation and chemotherapy as adjuvant treatment in patients with staged IB GC who were enrolled in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) trial. Materials and Methods: Among the 458 patients who were enrolled in the ARTIST trial, 99 had stage IB disease. The patients were randomly assigned to receive either adjuvant chemoradiotherapy with capecitabine plus cisplatin (XP, n=50) or chemoradiotherapy (XPRT, n=49). Survival analyses were performed in accordance with the AJCC 2010 staging system. Results: According to the AJCC 2010 system, stage migration from IB to II occurred in 71% of the patients; 98% of the T2 N0 cases were reclassified as T3 N0, and 42% of the T1 N1 cases were reclassified as T1 N2. When comparing survival outcomes between the XPRT and XP arms for stage IB cancer (AJCC 2002), no significant difference in 5-year disease-free survival (DFS) between the 2 arms was found. (median 5-year DFS, not reached, P=0.256). The patients classified as having stage IB cancer (AJCC 2002) and reclassified as having stage II cancer (AJCC 2010) exhibited worse prognoses than those who remained in stage IB, although the difference was not statistically significant (5-year DFS rate, 83% vs. 93%). When we compared 5-year DFS in 70 patients with stage II (AJCC 2010), the addition of radiotherapy to XP chemotherapy did not show better outcome than XP alone (P=0.137). Conclusions: The role of adjuvant chemoradiotherapy in the treatment of stage IB GC (AJCC 2002) warrants further investigation.

Development of analysis method for pyrifluquinazon residues in agricultural commodities

Se Ra Won,Nam Suk Kang,Yoon Jung Kang,Ho Won Chang,Sung Ho Woo,Hyang Min Ahn,Su Jin Kim,Su Zie Choi,Si Woo Bark,Gil Ran Kang,Gyeong Jun Kim,Jae I Kim,Tae Seok Kang,Woo Seong Kim 한국분석과학회 2016 학술대회논문집 Vol.2016 No.11

The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial

Kim, Youjin,Park, Se Hoon,Kim, Kyoung-Mee,Choi, Min Gew,Lee, Jun Ho,Sohn, Tae Sung,Bae, Jae Moon,Kim, Sung,Lee, Su Jin,Kim, Seung Tae,Lee, Jeeyun,Park, Joon Oh,Park, Young Suk,Lim, Ho Yeong,Kang, Won The Korean Gastric Cancer Association 2016 Journal of gastric cancer Vol.16 No.2

Purpose: In the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial, we investigated whether chemoradiotherapy after D2 gastrectomy reduces the rate of recurrence. Recently, the ratio of metastatic lymph nodes to examined lymph nodes (N ratio) has been proposed as an independent prognostic factor in gastric cancer (GC). The aim of this study was to investigate the relationship between the metastatic N ratio and prognosis of GC after curative D2 surgery. Materials and Methods: We retrospectively reviewed the data of 458 ARTIST patients who underwent D2 gastrectomy followed by adjuvant chemotherapy (XP, n=228) or chemoradiotherapy (XPRT, n=230). The disease-free survival (DFS) rates of patients were used to evaluate the influence of N ratio on the treatment outcome. To achieve this, 4 different N ratio categories (0%, 1%~9%, 10%~25%, and >25%) were compared on the basis of their influence on the treatment outcome. Results: On multivariate analysis, the N ratio remained an independent prognostic factor for DFS. The hazard ratios (HRs) for the N ratio categories of 0%, 1%~9%, 10%~25%, and >25% were 1, 1.061, 1.202, and 3.571, respectively. In patients having N ratio >25%, the 5-year DFS rates were 55% and 28% for the XPRT and XP arms, respectively (HR, 0.527; 95% confidence interval, 0.307~0.904; P=0.020). Conclusions: In patients with curatively resected GC, the N ratio was independently associated with DFS. Although this finding warrants further investigation in future prospective studies, the benefit of chemoradiotherapy for D2 resected GC appears to be more beneficial in cancers having N ratios >25%.

신이식술을 받은 임산부의 제왕절개술 마취경험 2 례

김원식,강성희,김세환,김경한,장태호 대한마취과학회 1994 Korean Journal of Anesthesiology Vol.27 No.7

The anesthetic management of the parturient with renal allograft depends on the degree of allograft impairment. Interaction of antirejection drug with stress of labor and anesthesia must also be considered. If graft function is normal, the anesthetic management is similar to that in normal pregnant patients. In patients with severe renal allograft compromise, large doses of bupivacaine should be avoided if an epidural block is contemplated. We have experienced one case of general anesthesia with enfiurane-nitrous oxide-oxygen and one case of epidural anesthesia with bupivacaine for cesarean seetion in renal transplsnted parturients witbout any gross ill effects to the mothers and newborns perioperatively. The anesthesia was managed with prophylactic antibiotics therapy, urinary catheterization after antiseptic pration, intravenous route with 18 gauge angiocath, steroid supplementation, protection from hypotension and avoidance of hyperglycemia. This report shows either general or epidural anesthesia can be successfully performed in parturient with renal allograft if preparations are properly done.

Clinical Significance of <i>IGFBP-3</i> Methylation in Patients with Early Stage Gastric Cancer ¹

Kim, Seung Tae,Jang, Hye-Lim,Lee, Jeeyun,Park, Se Hoon,Park, Young Suk,Lim, Ho Yeong,Choi, Min Gew,Bae, Jae Moon,Sohn, Tae Sung,Noh, Jae Hyung,Kim, Sung,Kim, Kyoung-Mee,Kang, Won Ki,Park, Joon Oh Neoplasia Press 2015 Translational oncology Vol.8 No.4

<P><I>BACKGROUND: IGFBP-3</I> is a multifunctional protein that inhibits growth and induces apoptosis of cancer cells. Hypermethylation of the promoter represses expression of the <I>IGFBP-3</I> gene. We undertook this study to assess the impact of <I>IGFBP-3</I> methylation on survival of early stage gastric cancer patients. <I>METHODS:</I> Of the 482 tissue samples from gastric cancer patients who underwent curative surgery, <I>IGFBP-3</I> methylation was tested in 138 patients with stage IB/II gastric cancer. We also analyzed IGFBP-3 methylation in 26 gastric cancer cell lines. <I>IGFBP-3</I> methylation was evaluated by methylation-specific polymerase chain reaction (MethyLight). Statistical analyses, all two-sided, were performed to investigate the prognostic effects of methylation status of the <I>IGFBP-3</I> promoter on various clinical parameters. <I>RESULTS:</I> Hypermethylation of <I>IGFBP-3</I> was observed in 26 (19%) of the 138 stage IB/II gastric cancer patients. Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the <I>IGFBP-3</I> promoter. Patients with a hypermethylated <I>IGFBP-3</I> promoter had similar 8-year disease-free survival compared with those without a hypermethylated <I>IGFBP-3</I> promoter (73% vs 75%, <I>P</I> = .78). In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with <I>IGFBP-3</I> methylation as compared with those without <I>IGFBP-3</I> methylation (8-year DFS: 55.6% vs 71.6%, <I>P</I> = .3694 and 8-year overall survival: 55.6% vs 68.4%, <I>P</I> = .491, respectively) even with no statistical significance. <I>CONCLUSIONS:</I> The status of <I>IGFBP-3</I> methylation as measured by methylation-specific polymerase chain reaction proposed the modest role for predicting survival in specific subgroups of patients with early-stage gastric cancer who undergo curative surgery. However, this needs further investigation.</P>

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

Kim, Seung Tae,Jang, Kee-Taek,Lee, Jeeyun,Jang, Heung-Moon,Choi, Hye-Jin,Jang, Hye-Lim,Park, Se Hoon,Park, Young Suk,Lim, Ho Yeong,Kang, Won Ki,Park, Joon Oh Neoplasia Press 2015 Translational oncology Vol.8 No.1

<P><I>BACKGROUND:</I> We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular subgroup analysis of treatment outcomes in patients who had specimens available for analysis was undertaken. <I>METHODS: Epidermal growth factor receptor</I> (<I>EGFR</I>), <I>KRAS</I>, and <I>PIK3CA</I> mutations were evaluated using peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp reactions. Survival and response rates (RRs) were analyzed according to the mutational status. Sixty-four patients (48.1%) were available for mutational analysis in the chemotherapy alone group and 61 (45.1%) in the chemotherapy plus erlotinib group. <I>RESULTS:</I> 1.6% (2/116) harbored an EGFR mutation (2 patients; exon 20), 9.6% (12/121) harbored a KRAS mutation (12 patients; exon 2), and 9.6% (12/118) harbored a PIK3CA mutation (10 patients, exon 9 and 2 patients, exon 20). The addition of erlotinib to GEMOX in patients with KRAS wild-type disease (<I>n</I> = 109) resulted in significant improvements in overall response compared with GEMOX alone (30.2% <I>vs</I> 12.5%, <I>P</I> = .024). In 95 patients with both wild-type KRAS and PIK3CA, there was evidence of a benefit associated with the addition of erlotinib to GEMOX with respect to RR as compared with GEMOX alone (<I>P</I> = .04). <I>CONCLUSION:</I> This study demonstrates that KRAS mutational status might be considered a predictive biomarker for the response to erlotinib in BTCs. Additionally, the mutation status of PIK3CA may be a determinant for adding erlotinib to chemotherapy in KRAS wild-type BTCs.</P>

A Voltage-Down Converter for Low-Voltage SoC

Won-jae Yi,Se-chul Lee,Tae-kyoung Kang,Gyu-Ho Lim,Yong Huh,Mu-Hun Park,Young-Hee Kim 대한전자공학회 2004 International Conference on Electronics, Informati Vol.2004 No.8

Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification

Kim, Seung Tae,Jang, Hye-Lim,Lee, Su Jin,Lee, Jeeyun,Choi, Yoon-La,Kim, Kyoung-Mee,Cho, Jeonghee,Park, Se Hoon,Park, Young Suk,Lim, Ho Yeong,Yashiro, Masakazu,Kang, Won Ki,Park, Joon Oh American Association for Cancer Research 2014 Molecular Cancer Therapeutics Vol.13 No.11

<P>Pazopanib is an orally bioavailable, ATP-competitive, multitargeted tyrosine kinase inhibitor mainly targeting VEGFR2 and PDGFR tyrosine kinases, but the biologic sequences of pazopanib activities beyond antiangiogenesis are poorly defined. We used a panel of 38 gastric cancer cell lines to test the efficacy of pazopanib. In a growth inhibition assay, genomic changes indicated that pazopanib had differential effects on cell growth. Treatment of the KATO-III, OCUM-2M, SNU-16, and HSC-39 gastric cancer cell lines harboring <I>FGFR2</I> amplification with pazopanib resulted in marked decreases of cell survival with IC<SUB>50</SUB> in ranges of 0.1 to 2.0 μmol/L, whereas the same treatment of those cell lines without <I>FGFR2</I> amplification had no growth-inhibitory effects. In the ectopic FGFR2-expressing model, treatment with the indicated concentrations of pazopanib significantly inhibited cell growth and colony formation by FGFR2-expressing NIH 3T3 cells with wild-type (WT) <I>FGFR2</I> and mutant <I>FGFR2</I> (S252W). Pazopanib also selectively suppressed constitutive FGFR2 signaling and phosphorylation of downstream effectors. In cell-cycle analysis, <I>FGFR2</I>-amplified cells underwent cell-cycle arrest at the G<SUB>1</SUB>–S phase after pazopanib treatment, whereas there were no significant effects on cell-cycle progression in cells without <I>FGFR2</I> amplification treated with pazopanib. In addition, pazopanib increased a substantial fraction of sub-G<SUB>1</SUB> only in <I>FGFR2</I>-amplified cells. These findings show that the activation of FGFR2 signaling by amplification may be a critical mediator of cell proliferation in a small subset of gastric cancer patients and that pazopanib may provide genotype-correlated clinical benefits beyond the setting of highly vascular tumors. <I>Mol Cancer Ther; 13(11); 2527–36. ©2014 AACR</I>.</P>